Core Viewpoint - The release of the "Guidelines for the Preparation and Quality Control of Tumor-Infiltrating Lymphocyte (TIL) Preparations" marks a significant step towards the standardized development of TIL technology in China, aiming to enhance the quality and efficiency of TIL treatments for patients with advanced solid tumors [5][6]. Group 1 - The event was co-hosted by the China Association for Medical Biotechnology and the Daxing Biomedical Industry Base, featuring prominent experts and officials from various institutions [1][3]. - TIL cell therapy offers new treatment options for patients with advanced solid tumors who cannot tolerate traditional chemotherapy, potentially allowing young cervical cancer patients to retain their uterus while achieving a cure [3][5]. - The Daxing Biomedical Industry Base is committed to supporting project implementation and results transformation, aiming to create an innovative cluster for cell therapy [3][6]. Group 2 - The formal release of the guidelines provides standards and norms for the preparation and quality control of TIL preparations, indicating a move towards regulatory compliance in the TIL field [5][6]. - A collaboration agreement was signed between the Xunsheng Medical Research Institute and the Beidaihe Rehabilitation Hospital's International Biomedical Center to enhance technical research and clinical applications of TIL [5][6]. - The Daxing Biomedical Industry Base hosts over 30 companies, with more than 60 products under research and 10 companies conducting over 20 clinical trials, showcasing its strength in cell therapy [6][7].